A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL ASSIGNMENT STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPARIXIN IN PANCREATIC ISLET AUTO-TRANSPLANTATION,

Registry ID

REP0112

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

DOMPÉ FARMACEUTICI S.P.A.

Start date

2013-12-13

Last update

2014-12-22

Conditions

• ISLET TRANSPLANTATION

Related clinical trials

• CEPOLYCLONAL REGULATORY T CELL (CEPOLYTREGS) IMMUNOTHERAPY IN ISLET TRANSPLANTATION
• POLYCLONAL REGULATORY T CELL (POLYTREG) IMMUNOTHERAPY IN ISLET TRANSPLANTATION
• CLINICAL STUDY USING ANTIAGING GLYCOPEPTIDE (PKX-001) IN ISLET TRANSPLANTATION
• "IMPROVING SINGLE DONOR SUCCESS RATE IN CLINICAL ISLET TRANSPLANTATION USING ALPHA-1 ANTITRYPSIN (ARALAST NP)."

View on source registry